CRF Health Wins Technology Company of the Year
News May 18, 2016
CRF Health, the leading global provider of eCOA solutions for the life sciences industry, today announced that it has won the Technology Company of the Year award at the 2016 Philadelphia Alliance for Capital and Technology (PACT) Enterprise awards. The honor recognizes CRF Health’s innovative technology solutions aimed at Life Science companies, strategic growth, as well as its go to market strategies which have propelled the company to become the global leader in electronic Clinical Outcomes Assessments for clinical trials.
The win comes the same week that CRF Health launches the latest addition to its technology portfolio, TrialConsent™, an industry-first electronic informed consent solution fully integrated within an eCOA platform.
The company’s CEO, Rachael Wyllie, commented, “We are delighted to have been named as the Technology Company of the Year, particularly in the same week that we launch our latest solution to the market. Our team focus on advancing innovation in our field and growing our suite of solutions focused on participants in the clinical trial process has resulted in this recognition. This, combined with the pharmaceutical industry’s growing recognition of the positive impact eCOA has on patient engagement and study success, keeps us forward focused and ensures we are the first choice eCOA partner for biopharmaceutical companies large and small.”
The PACT Enterprise Awards are presented annually and are one of the Greater Philadelphia region’s most prestigious business honors for the achievements of technology and life science companies, leaders and entrepreneurs. The Technology Company category recognizes outstanding leadership and product innovation, in addition to an organization’s financial accomplishments and contribution to its community and industry.
CRF Health’s eCOA solutions streamline complex processes and deliver reliable results for superior clinical trial outcomes. By improving patient engagement with intuitive design, supporting study teams with tailored scientific insights, and securing high quality data with precision, CRF Health is helping to ease the path to approval for many new medicines. Founded in 2000, the company is one of Philadelphia’s fastest growing technology companies with more than 550 staff in five locations across two continents.
For more information on CRF Health's eCOA solutions, please visit www.crfhealth.com.
About CRF Health
CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 800 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
The Genes That Make Quorn a Fungal Food FavoriteNews
The meat substitute Quorn is derived from a fungus called Fusarium venenatum. A very similar fungus, F. graminearum, is one of the world's most damaging crop diseases. A new genome study shows why one fungus makes food, and the other destroys it.READ MORE
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018